Peter Honig - 20 Jul 2021 Form 4 Insider Report for Sesen Bio, Inc. (CARM)

Role: Director
Signature: s/ Mark R. Sullivan, as attorney-in-fact
Issuer symbol: CARM
Transactions as of: 20 Jul 2021
Net transactions value: $0
Form type: 4
Filing time: 21 Jul 2021, 17:37:17 UTC
Next filing: 07 Dec 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CARM	Stock Option	Award	$0	+185,000		$0.000000	185,000	20 Jul 2021	Common Stock	185,000	$3.86	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on July 20, 2021 and vests monthly in equal amounts over a three-year period following the grant date. Based on market analysis by Radford of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion, the compensation committee of Sesen Bio, Inc. (the "Company") recommended to the Company's board of directors, and the board of directors approved, the amount of the initial grant to the reporting person in connection with the reporting person's appointment as a non-employee director.

Content

The option was granted on July 20, 2021 and vests monthly in equal amounts over a three-year period following the grant date. Based on market analysis by Radford of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion, the compensation committee of Sesen Bio, Inc. (the "Company") recommended to the Company's board of directors, and the board of directors approved, the amount of the initial grant to the reporting person in connection with the reporting person's appointment as a non-employee director.